|
Iressa Expanded Access Program (EAP) Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Iressa Expanded Access Program (EAP) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Iressa Expanded Access Program (EAP) Clinical research trials and Iressa Expanded Access Program (EAP) healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Iressa Expanded Access Program (EAP). Iressa Expanded Access Program (EAP) Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Iressa Expanded Access Program (EAP) clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Iressa Expanded Access Program (EAP) condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Iressa Expanded Access Program (EAP)  Iressa Expanded Access Program (EAP)
Iressa Expanded Access Program (EAP)
For Condition: Carcinoma, Non-Small-Cell Lung,Metastases, Neoplasm
Status: No longer recruiting
Sponsor(s): AstraZeneca ,
Synopsis: To provide single agent ZD1839 to patients with advanced (inoperable stage III or IV) non-small cell lung cancer who have failed standard treatment, or patients who can not receive other systemic anticancer therapy, or patients who are not medically suitable for chemotherapy, or because of either unavailability or ineligibility for other clinical trials with ZD1839 (e.g., poor performance status, lack of geographic proximity).
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Single Group Assignment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria For inclusion in this trial, patients must fulfill all of the following criteria: - previous documented histologically or cytologically confirmed non-small cell lung cancer; - locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV)patients who have received at least one course of standard systemic chemotherapy or radiation therapy or are ineligible for chemotherapy or radiotherapy or are ineligible or not a candidate for enrollment on another ZD1839 trial or who, in the Investigator's opinion, are not medically suitable for chemotherapy. - age 18 years or older; - written informed consent to participate in the trial. Exclusion Criteria Any of the following will exclude a patient from entering the trial: - receiving concurrent radiotherapy, chemotherapy, or other systemic anti-cancer medication or any other investigational agent. * Non-cytotoxic or hormonal therapies for the adjuvant treatment of cancer or for previously treated cancers may be allowed per AstraZeneca permission; - patients eligible for or previously enrolled on a ZD1839 blinded clinical trial protocol. Patients eligible for or previously enrolled on an open-label or unblinded ZD1839 clinical trial may be considered for acceptance into the Expanded Access Program with AstraZeneca permission; - having other active malignancies; - incomplete healing from previous oncologic or other major surgery; - evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial; - pregnancy or breast feeding (women of child-bearing potential).
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 1839IL/0050;
Study Start Date:
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034879
Other Carcinoma, Non-Small-Cell Lung Studies:
1. Evaluation of Bay 59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
2. A Phase II Clinical Trial of ABI-007, Administered Weekly in Taxol Resistant Patients with Metastatic Breast Cancer
3. Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer
4. Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
5. An open-label, multicenter, randomized, controlled study of an investigational drug in postmenopausal women with advanced breast cancer (ABC) having progressed on Tamoxifen.
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Michigan Clinical Trials
Other Roseville Clinical Trials
Iressa Expanded Access Program (EAP)
|
|
|
|
|
|
|
|
